References
- Centers for Disease Control and Prevention. Update: Influenza activity – United States, 2002–03 season. MMWR Morb Mortal Wkly Rep 2003;52:26–8
- Bridges CB, Harper SA, Fukuda K, et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003;52:1–34
- Simonsen L, Fukuda K, Schonberger LB, et al. The impact of influenza epidemics on hospitalizations. J Infect Dis 2000;181:831–7
- Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179–86
- Barker WH. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970–78. Am J Public Health 1986;76:761–5
- Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163:1667–72
- Neuzil KM, Mellen BG, Wright PF, et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000;342:225–31
- Tacken M, Braspenning J, Spreeuwenberg P, et al. Patient characteristics determine differences in the influenza vaccination rate more so than practice features. Prev Med 2002; 35:401–6
- Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999;282:1240–6
- Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 2000;355:1845–50
- Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000;283:1016–24
- Bowles SK, Lee W, Simor AE, et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999–2000. J Am Geriatr Soc 2002;50:608–16
- Sander B, Gyldmark M, Aultman R, et al. Impact on health outcome and costs of influenza treatment with oseltamivir in elderly and high-risk patients. J Med Econ 2004;7:67–83
- Vindt Holm M, Gyldmark M, Holme Hansen E. Pharmaco-economic assessment of oseltamivir in treating influenza – the case of otherwise healthy Danish adolescents and adults. Pharm World Sci 2004;26:339–45
- Rothberg MB, Bellantonio S, Rose DN. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. Ann Intern Med 2003;139: 321–9
- Smith KJ, Roberts MS. Cost-effectiveness of newer treatment strategies for influenza. Am J Med 2002;113:300–7
- Ortqvist A. Treatment of community-acquired lower respiratory tract infections in adults. Eur Respir J 2002;20\(Suppl 36):40s–53s
- Monto AS, Hornbuckle K, Ohmit SE. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol 2001;154:155–60
- Singh S, Barghoorn J, Bagdonas A, et al. Clinical benefits with oseltamivir in treating influenza in adult populations: results of a pooled and subgroup analysis. Clin Drug Invest 2003;23:561–9
- Monto AS, Rotthoff J, Teich E, et al. Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clin Infect Dis 2004;39:459–64